PDCD1LG2 antibody (APC)

Catalog No. ABIN2658153

Product Details anti-PDCD1LG2 Antibody (APC)

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PDCD1LG2 antibody is conjugated to APC

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Clone: MIH18

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for PDCD1LG2

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Alternative Name: CD273 (PDCD1LG2 Products)

Synonyms: PDL2 antibody, B7DC antibody, Btdc antibody, CD273 antibody, PD-L2 antibody, PDCD1L2 antibody, bA574F11.2 antibody, B7-DC antibody, F730015O22Rik antibody, programmed cell death 1 ligand 2 antibody, PDCD1LG2 antibody, Pdcd1lg2 antibody

Background: CD273, known as B7-DC, is also called programmed death ligand 2 (PDL2). This ligand is a 25 kD type I transmembrane protein and a member of B7 family within the immunoglobulin receptor superfamily and is expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. Clone MIH18 is reported to block PDL2.